Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

4D Pharma Appoints John Doyle As Chief Financial Officer

4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announces the appointment of John Doyle as Chief Financial Officer (CFO). Mr. Doyle brings over 15 years of experience leading and developing the financial operations, strategy and investor relations functions at public healthcare companies.

Recommended AI News: Sudrania Fund Services Surpasses 1,000 Employees, Opens Blockchain Laboratory


We are delighted to welcome John to 4D pharma at this exciting stage of the company’s growth, following our NASDAQ listing in 2021,” said Duncan Peyton, Chief Executive Officer of 4D pharma. “John’s extensive financial experience in diverse healthcare organizations and transformational events will be invaluable as 4D pharma continues to make progress in the clinic on multiple fronts with our Live Biotherapeutic programs.”

Related Posts
1 of 28,758

“I am honored to join a company that is committed to delivering a revolutionary class of medicines by harnessing bacteria from the microbiome,” said John Doyle, Chief Financial Officer of 4D pharma. “The 4D pharma team has built an impressive pipeline across key areas of high unmet need and I am excited for the opportunity to execute on the company’s growth strategy and financial goals.”

Recommended AI News: Riveting Feature Additions To Traderlo Marketplace For Developers And Design Community Worldwide

Mr. Doyle joins 4D pharma after serving as CFO at Chiasma Inc., a publicly traded biopharmaceutical company acquired by Amryt Pharma in 2021. Prior to Chiasma, John was Vice President of Finance and Investor Relations at Verastem Inc., a publicly traded biopharmaceutical company. Prior to joining Verastem in February 2018, he served as Head of Financial Planning & Analysis at SimpliVity Corp., a software company that was acquired by Hewlett Packard Enterprises in February 2017. Before that, Mr. Doyle was Director of Business Unit Financial Planning & Analysis, Early Phase Division, at PAREXEL, a publicly traded pharmaceutical contract research organization. Earlier in his career, he served in increasingly senior financial planning and analysis roles at Hologic, Inc., a publicly traded provider of medical diagnostic, surgical and imaging products. Mr. Doyle holds a B.S. in finance from the University of Massachusetts.

Recommended AI News: 5WPR Expands Consumer Retail Practice Area

 [To share your insights with us, please write to]

Comments are closed.